Association of patient- and hospital-level predictors with patterns of initial treatment in patients with rheumatoid arthritis: findings from a national cohort study
Authors' conclusion
In this cohort study of new-onset RA population, both individual- and institution-level variation in first-line csDMARD treatment strategy was evident.
Study context
- Population
- Newly diagnosed adult RA patients receiving csDMARD treatment, UK, 1 May 2018 to 1 April 2023
- Participants
- 15,462 participants
- Exposure
- First-line MTX monotherapy and MTX combination therapy vs non-MTX csDMARD prescription
- Outcome
- First-line csDMARD prescribing pattern and its associated individual and hospital factors
Methodological detailsnational cohort, adjusted multinomial logistic regression with random effect for hospital-level clustering
- National cohort
- Adjusted multinomial logistic regression with random effect for hospital-level clustering
Main finding
As reported in the abstract
Each group vs Non-MTXAdjusted odds ratio (95% CI)
MTX monotherapy
1.25(1.22–1.29)
MTX combination therapy
1.45(1.38–1.52)
- Variability in first-line csDMARD prescribing attributed to hospital level
- Around 20%
Observational data: associations, not effects.
Further findings
| Outcome | aOR (CI) | |
|---|---|---|
| MTX monotherapy vs MTX combination therapy, among those receiving MTXMTX monotherapyvs MTX combination therapyHigher DAS28 | 1.08 (1.05–1.11) | |
| MTX monotherapy vs MTX combination therapy, among those receiving MTXMTX monotherapyvs MTX combination therapyLung disease (monotherapy more likely without lung disease) | 0.5 (0.44–0.56) | |
| 0.512Adjusted odds ratio (log scale) |
Original publication
Association of patient- and hospital-level predictors with patterns of initial treatment in patients with rheumatoid arthritis: findings from a national cohort study. Rheumatology (Oxford). Published 24 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →